Medicare AdvantageCoverageMedium impact
MA08.019p, Intravenous Infliximab and Related Biosimilars
Independence Blue Cross·Gastroenterology, Rheumatology, Dermatology·Pharmacy
Effective date
Oct 1, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.019p regarding Intravenous Infliximab and Related Biosimilars has been updated with an effective date of October 1, 2025. The policy was posted and removed on the same day (November 17, 2025), suggesting this may be a correction or temporary update.
Action Required
By October 1, 2025: Billing team should access the full policy details at the provided URL to understand specific changes to infliximab and biosimilar coverage requirements. Review any updated prior authorization, documentation, or billing requirements for infliximab infusions. Monitor for additional policy updates given the same-day posting and removal.